Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PDE2A | O00408 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13326077 | 0.94 | KCNH3 (0.55) | KCNH3CA1CA2CA9L3MBTL1 | |
| SCHEMBL13325954 | 0.81 | APP (0.67) | KCNH3L3MBTL1SMN1; SMN2APPMAPT | |
| SCHEMBL30092962 | 0.80 | BCHE (0.79) | ALDH1A1KDM4EPOLBAPPMAPT | |
| SCHEMBL21567314 | 0.80 | BCHE (0.79) | ALDH1A1KDM4EPOLBAPPMAPT | |
| SCHEMBL7239012 | 0.80 | GAA (0.60) | CA1CA2CA9L3MBTL1ALDH1A1 | |
| SCHEMBL5888965 | 0.80 | PIK3CA (0.62) | KDM4ESMN1; SMN2APPMAPTTP53 | |
| SCHEMBL23431958 | 0.80 | ALDH1A1 (0.44) | KCNH3CA1CA2CA9L3MBTL1 | |
| SCHEMBL23431531 | 0.79 | MAPT (0.49) | L3MBTL1ALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL20406810 | 0.79 | PDE4A (0.62) | APP | |
| SCHEMBL13325955 | 0.78 | PIK3CA (0.51) | KCNH3CA1CA2CA9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718655-B2 | Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity | NEW YORK UNIVERSITY (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718655-B2 | Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity | NEW YORK UNIVERSITY (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718655-B2 | Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity | NEW YORK UNIVERSITY (US) | 2010-05-18 | — | — | US | disclosed |
| US-20040122009-A1 | Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity | NEW YORK UNIVERSITY (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122009-A1 | Trisubstituted triazine compounds, and methods for making and using the compounds, which have antitubulin activity | TUBA1C, TUBB1, TUBB | KCNH3 4016/4885CA1 2368/4885CA2 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.